Skip to main content

Zymeworks Inc 8-K, filed Nov 9, 2026

Zymeworks Inc. (ZYME)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Zymeworks Inc filed this 8-K on November 9, 2026.

Zymeworks raised 2026 revenue guidance to $337 million to $351 million and adjusted EBITDA guidance to $176 million to $190 million. Third-quarter revenue reached $256.5 million, primarily on a $250.0 million Ziihera milestone following first-line HER2-positive GEA approval. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits